We build cross-functional teams made up of research scientists, hardware and software engineers, physicians and commercial experts. Our multidisciplinary teams have access to advanced research tools, large scale computing power and unique technical expertise.
Andy Conrad, Ph.D.Chief Executive Officer View Bio
Andy Conrad, Ph.D.Chief Executive Officer
Formerly the chief scientific officer of LabCorp, Andy is a cell biologist with a doctorate from UCLA. He has always been passionate about early detection and prevention of disease. Andy co-founded the National Genetics Institute, which developed the first cost-effective test to screen for HIV in the blood supply.
Dimitri Azar, M.D., M.B.A.Clinical Lead,
Ophthalmology Programs View Bio
Dimitri Azar, M.D., M.B.A.Clinical Lead, Ophthalmology Programs
Dimitri Azar, M.D., M.B.A., is the clinical lead of Verily's Ophthalmology Programs and former dean of the University of Illinois College of Medicine. Dimitri is an ophthalmic surgeon who has made significant contributions to the treatment of corneal diseases and to advances in refractive surgery. He has served as a key adviser on the Novartis / Alcon and Verily ophthalmic lens projects since 2014. Dimitri completed his residency and fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. He was professor of Ophthalmology at Harvard Medical School before joining the University of Illinois as head of the Ophthalmology Department. Dimitri received his M.D. from American University of Beirut and his M.B.A. from University of Chicago, Booth School of Business.
Rob M. Califf, M.D., M.A.C.C.Advisor and
Advisory Board Member View Bio
Rob M. Califf, M.D., M.A.C.C.Advisor and Advisory Board Member
Robert M. Califf, M.D., M.A.C.C., is vice chancellor for health data science and director of Duke Forge, the Center for Actionable Health Data Science at Duke Health, Donald F. Fortin, M.D. Professor of Cardiology in the Duke University School of Medicine, chair of the board of the People Centered Research Foundation, and an advisor for Verily Life Sciences. He served as commissioner of the Food and Drug Administration in 2016-2017 during the Obama administration. Prior to joining the FDA, Rob was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He was founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Rob has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in peer-reviewed literature. Rob is a member of the National Academy of Medicine (formerly the Institute of Medicine). He has led major initiatives aimed at improving methods and infrastructure for clinical research and served on many NIH advisory committees, including the Institutes of Aging, National Heart, Lung and Blood Institute, National Cancer Institute and National Library of Medicine.
Ashraf Hanna, M.D., Ph.D.Chief Operating Officer View Bio
Ashraf Hanna, M.D., Ph.D.Chief Operating Officer
Ashraf Hanna is the chief operating officer of Verily. Previously he was the CEO of ORIC Pharmaceuticals, a company focused on the development of treatments for cancer resistance. Before that Ashraf spent nearly 11 years as a Vice President at Genentech leading the Commercial and Medical Affairs Finance functions, as well as Alliance Management and Portfolio Planning group, which is responsible for developing metrics and process for guiding R&D investments. Ashraf was also the CFO for the Genentech foundation, and previously at McKinsey and Company. He is a graduate of University of Chicago, has a Ph.D. in Physics from Harvard University and an M.D. from the University of Massachusetts.
Sheela KrothapalliHead of People Operations View Bio
Sheela KrothapalliHead of People Operations
Sheela leads Verily's People Operations team providing strategic HR partnership to the business, and overseeing the recruiting function. The team ensures that Verily has the talent, operational support, and people programs to grow and execute. Prior to joining Verily as its first dedicated People Ops hire, Sheela spent over seven years working at Google. Sheela has a B.S. from Cornell University in Industrial and Labor Relations, and also studied International Relations and Law.
Vivian Lee, M.D., Ph.D., M.B.A.President, Health Platforms View Bio
Vivian Lee, M.D., Ph.D., M.B.A.President, Health Platforms
Vivian S. Lee, M.D., Ph.D., M.B.A., works closely with Verily's clinical and engineering teams to develop products and platforms that can support health system improvement and advance population health. Formerly, as dean, SVP and CEO, she led University of Utah Health, an integrated health system, academic campus, and health plan that has been recognized for its health care innovations and ranked first among university hospitals in quality and safety. As a healthcare executive and over her career as an NIH-funded MRI researcher, she has published a textbook and over 180 articles in leading journals including JAMA and New England Journal of Medicine. Vivian was elected to the National Academy of Medicine in 2015. A Rhodes Scholar, she is a graduate of Harvard-Radcliffe Colleges, Oxford University, Harvard Medical School, and NYU Stern School of Business.
Jessica Mega, M.D., M.P.H.Chief Medical and
Scientific Officer View Bio
Jessica Mega, M.D., M.P.H.Chief Medical and Scientific Officer
Jessica L. Mega, M.D., M.P.H., is the chief medical and scientific officer of Verily. As CMSO, Jessica's focus is on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. She oversees all of Verily's clinical and science efforts, including the Baseline Study. As a faculty member at Harvard Medical School, a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women's Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. She also directed the TIMI Study Group's Genetics Program. Her findings have been published in the New England Journal of Medicine, Lancet, JAMA, and elsewhere. Jessica sits on the advisory group for the California Governor on Precision Medicine. She is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health.
Oran MudurogluBusiness Lead, Health Platforms View Bio
Oran MudurogluBusiness Lead, Health Platforms
Oran is focused on architecting products and partnering strategies that support health system improvement and impact population health. Oran has over 20 years of industry experience, successfully launching multiple startups focused on improving the quality of and access to healthcare. Prior to joining Verily, Oran was the CEO of Medicalis, which was acquired by Siemens in 2017. Previously, Oran was the CEO of Patient Monitoring and Healthcare Informatics at Philips Medical Systems. Oran received his B.S. Hons, in Engineering, from King's College London.
Brian Otis, Ph.D.Chief Technical Officer View Bio
Brian Otis, Ph.D.Chief Technical Officer
Brian's team focuses on end-to-end innovation ranging from integrated circuits to biocompatible materials to sensors. Brian leads the company's efforts across all hardware and device projects, including wearables, implanted devices and technology. He joined Verily from the University of Washington Department of Engineering. Previously, Brian held positions at the University of Washington Kelly Tremblay Brain and Behavior Laboratory, the UC-Berkeley Ralph Freeman Neuroscience Lab, Intel Corporation and Agilent Laboratories. He received his M.S. and Ph.D. in Electrical engineering, in the field of low power integrated circuits for wireless sensors, from the University of California, Berkeley.
Tom StanisHead of Software View Bio
Tom StanisHead of Software
Tom leads all of Verily's software projects, including the development of machine learning algorithms for applications ranging from robotic-assisted surgery to diabetes management. Prior to joining Verily, he spent nine years working on core Google products and five years at Electronic Arts. Throughout his career, Tom's focus has been on improving the user experience, performance and scalability of systems through cross-functional collaboration. He received his B.S. from UW Madison.
Linus UpsonHead of Engineering View Bio
Linus UpsonHead of Engineering
Linus Upson joined Google in 2005 and is a vice president at Verily. He leads Verily's Debug Project and oversees engineering and user experience. Earlier he was responsible for overseeing Google's browser products including Chrome and Chrome OS. Prior to Google, Linus was an engineer at NeXT and Netscape and co-founded two companies, AvantGo and Qurb. Linus is on an extended leave from his undergraduate studies in mathematics at Princeton University.
Claudia WalshGeneral Counsel View Bio
Claudia WalshGeneral Counsel
Claudia leads the legal department and oversees general and administrative functions at Verily. She's a deal lawyer that joined Google in 2007, where she supported the strategic partnerships organization across a variety of product areas. She took over leadership of the X legal team in 2014 and shifted fully to Verily in 2015. Prior to Google she practiced corporate law at Morrison & Foerster in Palo Alto. She received her B.A. from Stanford University and J.D. from University of California, Hastings College of the Law.
Carolyn WangHead of Communications View Bio
Carolyn WangHead of Communications
Before leading communications and marketing at Verily, Carolyn was President of Brewlife, a W2O Group agency. There she focused on strategic branding and communications consulting for emerging brands, predominantly in life sciences and healthcare. Prior to Brewlife, Carolyn helped to build the digital health group within WCG, another W2O Group agency, where she led the healthcare practice. Carolyn received her B.S. in biology from Elon University.
Duncan Welstead, M.B.A.Chief Financial Officer View Bio
Duncan Welstead, M.B.A.Chief Financial Officer
Duncan joined Verily in 2014 and leads the finance team. Previously, Duncan worked in finance at YouTube with a focus on content licensing & partnerships. Prior to Alphabet, Duncan worked in private equity investing with Halyard Capital, a mid-market growth equity firm, and in investment banking at BMO Capital. Duncan completed his M.B.A. at Columbia Business School and graduated with a B.S. in Mechanical Engineering from Brown University.
Dennis Ausiello, M.D.View Bio
Dennis Ausiello, M.D.
Dennis A. Ausiello, M.D., is the Jackson Distinguished Professor of Clinical Medicine and director emeritus of the MD/PhD Program at Harvard Medical School. He is also chairman of Medicine emeritus and director of the Center for Assessment Technology and Continuous Health (CATCH) at the Massachusetts General Hospital (MGH). This center is a partnership among MGH, MIT, and Harvard University whose mission is to develop real-time assessment of human traits in wellness and disease. A graduate of Harvard and the University of Pennsylvania, Dennis is a nationally recognized leader in academic medicine who understands the needs for partnerships between the academy and industry.
Linda AveyView Bio
Linda Avey is co-founder & CEO of Precise.ly, a precision medicine engine providing deep genetic insights to patients with chronic conditions. The company's goal is to identify disease subtypes leading to more precise diagnoses and treatments. In 2006, Avey co-founded 23andMe, the leading direct-to-consumer genetics company. The idea for 23andMe came during her tenure at Affymetrix and Perlegen Sciences, where she observed gaps in the US research model that could be solved through a web- and consumer-based approach. 23andMe now houses the world's largest genetic database with 80% of its participants powering the research mission. Prior to 23andMe, Linda had over 25 years' experience working with the biopharmaceutical and academic research industry.
Hal Barron, M.D.View Bio
Hal Barron, M.D.
Hal V. Barron, M.D., joined GSK as chief scientific officer and president, R&D on in January 2018. He is a member of the board and the corporate executive team. His previous role was president, R&D at Calico (an Alphabet-backed life sciences company). Prior to this, Hal was executive vice president, head of Global Product Development, and chief medical officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was senior vice president of Development and chief medical officer. Hal was previously a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics, Inc. He is associate adjunct professor, Epidemiology & Biostatistics, University of California, San Francisco. Hal holds a B.S. degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Josephine Briggs, M.D.View Bio
Josephine Briggs, M.D.
Josephine P. Briggs, M.D., is director emeritus of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH), the leading federal agency for research on integrative and complementary health practices. An accomplished researcher and physician, Josephine served as director of NCCIH from 2008 to 2017.
Tan Chorh Chuan, M.D., Ph.D.View Bio
Tan Chorh Chuan, M.D., Ph.D.
Professor Tan Chorh Chuan was appointed the inaugural chief health scientist and executive director of the new Office for Healthcare Transformation in Singapore's Ministry of Health in January 2018. He was president of the National University of Singapore from 2008 to 2017. He previously served as director of Medical Services, Ministry of Health (2000-2004), where he led the public health response to the SARS epidemic. His awards include the National Science and Technology Medal (2008) and he was elected an international member of the US National Academy of Medicine in 2015. A renal physician, he obtained his medical training at National University of Singapore, and research training at the Institute of Molecular Medicine, Oxford.
Karen DeSalvo, M.D., M.P.H., M.Sc.View Bio
Karen DeSalvo, M.D., M.P.H., M.Sc.
Karen B. DeSalvo, M.D., M.P.H., M.Sc. is a physician whose career has been dedicated to improving the health of all people, with a particular focus on vulnerable populations, through patient care, education, policy and administrative roles, research, and public service. She is currently professor of Medicine and Population Health at the University of Texas at Austin Dell Medical School. Karen served as acting assistant secretary for Health and also the National Coordinator for Health Information Technology at the U.S. Department of Health and Human Services during the Obama Administration. She was previously New Orleans Health Commissioner and vice dean for Community Affairs and Health Policy at Tulane School of Medicine.
Kathy Giusti, M.B.A.View Bio
Kathy Giusti, M.B.A.
Kathy Giusti, a multiple myeloma patient, is the founder and chief mission officer of the Multiple Myeloma Research Foundation (MMRF) and serves on its board of directors. Kathy has led the MMRF in establishing collaborative research models in the areas of tissue banking, genomics, and clinical trials that are dramatically accelerating the pace at which life saving treatments are brought to patients. She also leads the Kraft Precision Medicine Accelerator, a $20M endowed program at Harvard Business School (HBS) that is developing business models to speed breakthroughs in precision medicine for all cancers. Kathy was ranked among Fortune magazine's "World's 50 Greatest Leaders" and listed as one of TIME magazine's "100 Most Influential People in the World." She received her M.B.A. from HBS and holds an honorary Doctorate from the University of Vermont.
Phil Nelson, Ph.D.View Bio
Phil Nelson, Ph.D.
Phil Nelson is a director of Engineering in Google Research. He joined Google in 2008 and was previously responsible for a range of Google applications and geo services. In 2013, he help found and currently leads the Google Accelerated Science team that collaborates with academic and commercial scientists to apply Google's knowledge and experience running complex algorithms over large data sets to important scientific problems. Philip graduated from MIT in 1985 where he did award-winning research on hip prosthetics at Harvard Medical School. Before Google, Philip helped found and lead several Silicon Valley start-ups in search (Verity), optimization (Impresse), and genome sequencing (Complete Genomics) and was also an entrepreneur in residence at Accel Partners.
Steve Oesterle, M.D.View Bio
Steve Oesterle, M.D.
Steve N. Oesterle is a venture partner at NEA and serves as a senior advisor to EQT Partners and Temasek Holdings. He is currently a board director at Baxter International and Reva Medical. He was formerly SVP for Medicine and Technology at Medtronic, and a member of its Executive Operating Committee for 14 years. He oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of Medtronic's Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic, Steve served on more than 20 boards as a director or observer. Steve graduated summa cum laude from Harvard and received his M.D. from Yale; he completed his residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.
Andy Slavitt, M.B.A.View Bio
Andy Slavitt, M.B.A.
During his decades-long career as a private sector healthcare technology leader, including as group executive VP for Optum, Andy Slavitt drove some of the most significant and successful initiatives in healthcare, impacting millions of Americans as well as the shape of the healthcare system. He was the former acting administrator of the Centers for Medicare and Medicaid Services under President Obama. Prior to that he was the group executive vice president of Optum, and before that a healthcare tech founder and entrepreneur. Andy is currently general partner at Town Hall Ventures and serves as board chair of United States of Care, a national non-profit health advocacy organization he founded. Andy leads a number of national health care initiatives, including one on the future of health care, which he co-chairs at the Bipartisan Policy Center. Today he is a highly recognizable voice in healthcare, with a regular column in the USA Today and regular appearances on CNN, MSNBC and Fox. Andy graduated from the College of Arts and Sciences and the Wharton School at the University of Pennsylvania and holds an M.B.A. from the Harvard Business School. He was recently named a Distinguished Policy Fellow at the University of Pennsylvania.
Eric Topol, M.D.View Bio
Eric Topol, M.D.
Eric J. Topol is executive vice president of the Scripps Research Institute, professor of Molecular Medicine, and the founder and director of the Scripps Translational Science Institute. He has published over 1100 peer-reviewed articles, with more than 200,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. He started a new medical school in 2004 and is currently a leader of the NIH Precision Medicine Initiative of 1 million Americans. He has published 2 bestseller books on the future of medicine: The Creative Destruction of Medicine and The Patient Will See You Now.
Daniel Von Hoff, M.D., F.A.C.P.View Bio
Daniel Von Hoff, M.D., F.A.C.P.
Daniel D. Von Hoff, M.D., F.A.C.P. is currently physician in chief, distinguished professor Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also chief scientific officer for HonorHealth Clinical Research Institute and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research. He is the medical director of research at McKesson Specialty Healthcare and the scientific medical officer for US Oncology Research and leader of the Translation Oncology Program (TOP) specializing in phase I clinical trials done in the US Oncology Research network. Daniel is also currently the Senior Consultant-Clinical Investigations for City of Hope. He also holds an appointment as professor of Medicine, Mayo Clinic, Scottsdale, AZ.